NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer TrialBenzinga • 06/02/25
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual MeetingBusiness Wire • 05/31/25
Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual MeetingBusiness Wire • 05/31/25
1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall StreetThe Motley Fool • 05/28/25
Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?Zacks Investment Research • 05/15/25
Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High?Zacks Investment Research • 04/29/25
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025Benzinga • 04/24/25
NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 04/24/25
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual MeetingBusiness Wire • 04/23/25
Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung CancerBusiness Wire • 04/22/25
NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 04/17/25
Novocure to Participate in Leerink Partners 2025 Global Healthcare ConferenceBusiness Wire • 03/04/25
NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research • 02/27/25